Synexa buys Alderley Analytical in latest bioanalysis deal
Glide Healthcare-backed biomarker services firm Synexa Life Sciences, has bought UK-based Alderley Analytical, citing its capabilities and customer base as drivers.
The deal – which financial terms were not disclosed – will add Alderley’s range of bioanalytical services for discovery, preclinical, and clinical drug development projects to Synexa’s offering.
Synexa CEO Emile Lens said, “By combining two very complementary companies, the group can now offer an even more comprehensive range of services to an enlarged customer base, both in large and small molecule drug development and ranging from pre-clinical work to Phase III clinical studies.”
This was echoed by Paul Holme, CEO and co-founder of Alderley Analytical, who said, “This step represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”
Synexa’s current offering is focused on biomarker and bioanalytical assays, covering DNA, RNA, protein, cell and tissue analysis.
Alderley Analytical provides bioanalytical services, describing itself as a specialist in mass spectrometry and ligand binding assays. The firm relocated to a GLP/GCP-accredited laboratory in Tytherington Business Park near Manchester in 2023.
Acquisition
Tom Klein Robbenhaar, a partner at Gilde Healthcare, welcomed the deal and hinted the firm would be making more acquisitions.
“Adding the LC/MS capabilities of Alderley to the existing broad bioanalytical capabilities of Synexa is a great and complementary addition for both clients and employees. We are excited to partner with the Alderley team, invest in the Manchester operations, and combine Alderley’s and Synexa’s scientific excellence.
“This is a great acquisition for Synexa, and we look forward to teaming up with more leading bioanalytical service providers,” Robbenhaar said.
Prior to buying Alderley, Syenxa’s acquired Finland-based bioanalysis services firm Syrinx Bioanalytics in 2022.
DepositPhotos/pichetw